Allan Bradley, T-Therapeutics CEO

Sanofi-backed T-Ther­a­peu­tics bags $59M in Se­ries A to un­lock po­ten­tial of TCR ther­a­peu­tics: #Jef­feries23

LON­DON — T-Ther­a­peu­tics has raised £48 mil­lion ($59 mil­lion) in a Se­ries A round sup­port­ed by a Big Phar­ma in­vestor to dis­cov­er and de­vel­op new T cell re­cep­tor (TCR) ther­a­peu­tics us­ing its trans­genic mouse tech­nol­o­gy.

The round was co-led by Sofinno­va Part­ners, F-Prime Cap­i­tal, Dig­i­tal­is Ven­tures and Cam­bridge In­no­va­tion Cap­i­tal with con­tri­bu­tions from Sanofi Ven­tures and the Uni­ver­si­ty of Cam­bridge Ven­ture Fund. T-Ther­a­peu­tics will use the cash to ad­vance drugs for can­cer and in­flam­ma­to­ry dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.